Effectiveness of sorafenib in the treatment of hepatocellular carcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter P. Salamanca
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors P. Salamanca1, H. Magalhães2, F. Carneiro1, D. Marques2, C. Faustino2, N. Sousa2, M. Machado2, P. Ferreira2, A. Raimundo2, M. Fragoso2, L. Lara Santos3, D. Pereira1
  • 1Portuguese Institute of Oncology FG Porto, Portugal - Medical Oncology Service, Porto, Portugal, /
  • 2IPO-Porto, Porto, Portugal, /
  • 3Portuguese Institute of Oncology FG Porto, Portugal - Surgical Oncology Service, Porto, Portugal, /

Abstract

Unresectable hepatocellular carcinoma (HCC) is one of the tumors with worst prognosis, with five-year survival rates lower than 20%. Sorafenib is a multikinase inhibitor with antiproliferative and antiangiogenic properties approved for the treatment of advanced HCC or HCC progressing after local-regional treatments.